Council Implementing Decision (EU) 2015/1875 of 8 October 2015 on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2- (ethylamino)cyclohexanone (methoxetamine) to control measures

Article 1	The following new psychoactive substances shall be subjected to
	control
Article 2	Decision 2014/688/EU is replaced, without prejudice to the
	obligations of
Article 3	This Decision shall enter into force on the day following
	Signature

Changes to legislation: There are currently no known outstanding effects for the Council Implementing Decision (EU) 2015/1875. (See end of Document for details)

- (1) OJ L 127, 20.5.2005, p. 32.
- (2) Council Decision 2003/847/JHA of 27 November 2003 concerning control measures and criminal sanctions in respect of the new synthetic drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2 (OJ L 321, 6.12.2003, p. 64).
- (3) Judgment of the Court of Justice of 16 April 2015, Parliament v Council, Joined Cases C-317/13 and C-679/13, ECLI:EU:C:2015:223.
- (4) Council Implementing Decision 2014/688/EU of 25 September 2014 on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures (OJ L 287, 1.10.2014, p. 22).

Changes to legislation:

There are currently no known outstanding effects for the Council Implementing Decision (EU) 2015/1875.